cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Springworks Therapeutics Inc
2 own
6 watching
Current Price
$42.43
$-1.68
(-3.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,698.14M
52-Week High
52-Week High
53.92000
52-Week Low
52-Week Low
18.00000
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,698.14M
icon52-Week High53.92000
icon52-Week Low18.00000
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Springworks Therapeutics Inc do?
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More
How much money does Springworks Therapeutics Inc make?
News & Events about Springworks Therapeutics Inc.
Globe Newswire
1 year ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) on behalf of the companys long-term investors. The investigation seeks to determine whether SpringWorks has issued false and misleading statements and/or ...
Globe Newswire
1 year ago
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission ...
PR Newswire
1 year ago
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma PR Newswire CONCORD, Mass...
Frequently Asked Questions
Frequently Asked Questions
What is Springworks Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Springworks Therapeutics Inc shares?
plus_minus_icon
How can I buy Springworks Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Springworks Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Springworks Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Springworks Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Springworks Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Springworks Therapeutics Inc?
plus_minus_icon
What percentage is Springworks Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Springworks Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$42.43
$-1.68
(-3.81%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00